Ovarial function in pts with systemic lupus erythematosus
https://doi.org/10.14412/1995-4484-2004-1469
Abstract
Objective. To assess ovarian function and its changes during therapy with cyclophosphan (CPh) in pts with systemic lupus erythematosus (SLE). Material and Methods. 44 pts with SLE aged 16 to 45 years with intact menstrual cycle were examined. 18 from them had received CPh earlier (mean cumulative dose 5,7 g), 26 had been never treated with CPh. Mean age, disease duration and activity (according to SLEDAI) as well as glucocorticoid (GC) doses were similar in both groups. Blood sex hormones - follicle-stimulating hormone (FSH), lutropin (LT), prolactin, estradiol, progesterone were tested with immune-enzyme assay. Each pt was examined by a gynaecologist, pelvis minor ultrasonography was performed, basal temperature was measured during 3 months Results. CPh treated pts had lower mean progesterone levels but higher FSH and LT than pts that had not received CPh. Intensity of these changes depended on cumulative dose of CPh and age of pts. Failure of menstrual cycle lutein phase was found with similar frequency in both groups and achieved in average 63%. Oligomenorrhea and more than twofold menstrual cycle shortening were present more frequently in pts treated with CPh (p<0,05). Conclusion. Treatment with CPh increase risk of ovarian dysfunction in pts with SLE. Failure of menstrual cycle lutein phase does not exclude autoimmune genesis of oophoritis in SLE.
References
1. <div><p>Алекберова З.С., Карабаева А.С., Кошелева Н.М. СКВ: начало улиц в возрасте старше 45 лет. Клин, геронтол., 2002, 8, 3, 16-21</p><p>Алекберова З.С., Кошелева Н.М., Белецкая С.Г. Мониторинг активности СКВ при беременности. Тер. архив, 1994, 10, 46-51</p><p>Алекберова З.С., Фоломесв М.Ю. Половой диморфизм при ревматических заболеваниях. Ревматол., 1985, 2, 58-61</p><p>Насонов Е.Л., Клюквина Н.Г., Масенко В.П. Пролак- тин при ревматических заболеваниях. Клин.ревматология, 1997,2, 23-28</p><p>Alirned Ebbiary N.A., Lemon Е.А., Sail С. The significance of elevated basal follicle stimulating hormone in regularly menstruating infertile women. Hum Reprod., 1994. 9, 245252</p><p>Ataya K.M., Valeriote F.A. Ramahi-Ataya A. Effects of cyclophosphamide on immature rat ovary. Cancer Res., 1989, 49,1660-1664</p><p>Axelrod L. Glucocorticoid therapy. Medicine, 1976, 55, 3965</p><p>Bakchine H , Brauncr R., Thibaud E. et al. Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease. Arch. Fr. Pediatr., 1986, 43, 611-616</p><p>Beeson P.B. Age and sex associations of 40 autoimmune diseases. Am. J. Med., 1994, 96, 457-462</p><p>Blanco Favela F., Quintal-Alvarez G, Leanos-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power J. Rheumatol., 1999, 26, 55-59</p><p>Bounipas D.T., Austin H.A., Vaughn E.M. et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med., 1993, 119, 366-369</p><p>Buyon J.P., Wallace D.J. The endocrine system, use of exogenous estrogens, and the urogenital tract. In Dubois’ Lupus erythematosus. Baltimore, MD, Williams & Williams, 1997, 817-834</p><p>Davis J.C., Klippel J.H. Antimalarias and immunosupres- sive drugs. In Labita R G (ed). Systemic lupus erythematosus, ed 3. San Diego, Academic Press, 1999, 967-984</p><p>Derivation of the SLEDA1. A disease activity index for lupus patients. Bombardier С. Gladman D.D., Urowitz et al. Arthr. Rheum , !<>92 35, 630-640</p><p>Formiga F., Moga I. Рас M Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus, 1999, 8, 462-465</p><p>Gallant C., Kenny P. Oral glucocorticoids and their complication. A review. J. Am. Acad. Dermatol., 1986, 14, 161— 177</p><p>Gonzalez-Crespo M.R., Gomez-Reino J.J., Merino R. et al: Menstrual disorders in gerls with systemic lupus erythematosus. Br. J. Rheumatol., 1995, 34, 737-743</p><p>Greenstein B.D. Lupus: Why women? J. Women's Health, 2001, 10, 3, 233-239</p><p>Huong Du Le Thi, Amoura Z, Duhaut P. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J. Rheumatol., 2002, 29, 12, 25712576</p><p>Jewelewiez R., Schwartz M. Premature ovarian failure. Bull. N Y. Acad. Med., 1986, 62, 219-236</p><p>Katsifis G., Tzioufas A.G., loannidis J.P.A. Parameters modulating the risk of sustained amenorrea from pulsed intravenous cyclophosphamide in premonopausal women with systemic lupus erythematosus, [abstract]. Clin. Exp. Rheumatol., 2002, 20, 2, 267</p><p>Lado-Abeal J„ Rodrigues-Arnao J., NeweU-Price J.D. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgens levels. J. Clin. Endocrinol. Metab., 1998, 83. 3083-30S8</p><p>Lahita R.G. Gender and age in lupus. In Lahita RG(ed). Systemic lupus erythematosus, ed 3. San Diego, Academic Press, 1999, 129-144</p><p>Lahita R.G. Sex hormones and systemic lupus erythematosus. Rheum. Dis. Clin. North. Am., 2000, 26, 4, 951968</p><p>Lenton E.A., Sexton L., Lee S. Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. Maturitas., 1988, 10, 35-43</p><p>Lim G.S., Petri М., Goldman D. Menstruation and systemic lupus erythematosus (SLE): a case-control study, [abstract]. Arth. Rheum., 1993, 36 (suppl 5), R23</p><p>Manzi S., Meilahn E., Rairi J. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am. J. Epidemiol., 1997, 145, 408-415</p><p>McDermott E.M., Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann. Rheum. Dis., 1996, 55, 224- 229</p><p>Мок C.C., Lau C.S., Ho C.T.K. Do flares of systemic lupus erythematosus decline after menopause? Scand. J. Rheumatol., 1999, 28, 357-362</p><p>Мок C.C., Lau C.S., Wong R,W. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapv. Arlhr. Rheum., 1998, 41, 831-837</p><p>Мок C.C., Wong R.W., Lau C.S. Ovarian failure and flares of systemic lupus erythematosus. Arth. Rheum., 1999, 42, 1274-1280</p><p>Molitch M.E. Pathologic hyperprolactinemia. Endocrinol. Metab. Clin. N. Am., 1992, 21, 877-901</p><p>Moncayo-Naveda H., Moncayo R., Benz R. Organ-specific antibodies against ovary in patients with systemic lupus erythematosus. Am. J. Obstet., 1989, 160, 1227-1229</p><p>Morris V.H., Hakim A. Isenberg D.A. Rewiew of gynaecological abnormalities in patients with systemic lupus erythematosus. Arthr. Rheum,, 1997, 40, 106</p><p>Nelson A.M., Conn O.L. Glucocorticoids in rheumatic disease. Mayo Clin. Proc., 1980, 55, 758-769</p><p>Pasoto S.G., Mendonca B.B., Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus, 2002, 11, 175-180</p><p>Pasoto S.G., Viana V.S., Mendonca B.B. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J. Rheumatol., 1999, 26, 1087-1093</p><p>Pekopen F,, Siegberg R-, Makinen T. Immunological disturbances in patients with premature ovarian failure. Clin. Endocrinol., 1986, 25, 1-6</p><p>Petri М., Howard D., Rcpke J. Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthr. Rheum., 1999, 42, 1274-1280</p><p>Plotz C.M., Knowlton A.I., Ragan C. The natural history of Cushing's syndrome. Am. J. Med., 1952, 13, 597-614</p><p>Rose E., Pillsbury D.M. Lupus erythematosus and ovarian function: observations on a possible relationship, with report of six cases, Ann, Intern. Med., 1944. 21. 1022-1034</p><p>Saketos М., Sharma N., Santoro N.F. Suppression of the hypothalamic-pituitary-ovarian axis in normal women by glucocorticoids. Biol. Reprod., 1993, 49, 1270-1276</p><p>Schaller J. Lupus in childhood. Clin, Rheum. Dis., 1982, 8, 219-228</p><p>Scully R.E., Mark E.J., McNeely B.U. Case records of the Massachusetts General Hospital. Case 46-1986. New Engl. J. Med., 1986, 315, 1336-1343</p><p>Silva C.A.A., Leal M.M., Leone C. Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus, 2002, II, 419-425</p><p>The 1982 revised criteria for the classification of systemic lupus erythematosus. Tan E.M., Cohen A.S., Fries J.S. et al. Arthr. Rheum, 1992, 25, 1271-1277</p><p>Van V.R., McGuire J.L. Estrogen, progesteron, and testosterone: Can they be used to treat autoimmune diseases? Cleve Clin. J. Med., 1994, 61, 276-284</p><p>Verthelyi D, Sex hormones as immunomodulators in health and disease. Intern. Immunopharmacol., 2001, I, 983-993</p><p>Wallace D.J., Dubois E.L. Clinical and laboratory manifestations of SLE. In Dubois’ Lupus Erythematosus, ed 3. Philadelphia, PA, Lea & Febiger, 1987, 317-449</p><p>Wang C.L., Wang F., Bosco J.J. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus, 1995, 4, 11-14</p></div><br />
Review
For citations:
Sliabanova S.Sh., Alekberova Z.S., Guzov I.I., Ananyeva L.P. Ovarial function in pts with systemic lupus erythematosus. Rheumatology Science and Practice. 2004;42(3):4-9. (In Russ.) https://doi.org/10.14412/1995-4484-2004-1469
Views:
1112
Email this article 